Anavex Life Sciences Corp

AVXL remains entrenched in a Stage 4 decline with active lower highs and lower lows under declining EMAs. Both medium-term and long-term directional biases are bearish, and with price trading near support and below key EMAs, execution should be deferred until rallies into the declining 9/21 EMA resistance zone for a rejection-based trim entry.

• ↑Focus on novel Alzheimer’s and CNS drugs addresses unmet market need
• ↑PVG proxy campaign could install experienced management, aiding strategy execution
• ↓Deeply negative earnings yield and weak profitability factors raise financial concerns